{
  "success": true,
  "sourceFile": "input/trial/NCT04573309_Wilsons/NCT04573309_Wilsons_SAP.pdf",
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33
  ],
  "modelUsed": "gemini-3-flash-preview",
  "sapData": {
    "analysisPopulations": [
      {
        "id": "pop_1",
        "name": "Screened Set",
        "text": "The Screened Set includes all participants who signed the informed consent form (ICF).",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "Screened Set",
        "populationDescription": "The Screened Set includes all participants who signed the informed consent form (ICF).",
        "criteria": "Signed Informed Consent Form (ICF)"
      },
      {
        "id": "pop_2",
        "name": "Enrolled Set",
        "text": "The Enrolled Set includes all participants who signed the ICF and were enrolled in the study.",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "Enrolled Set",
        "populationDescription": "The Enrolled Set includes all participants who signed the ICF and were enrolled in the study.",
        "criteria": "Signed ICF AND enrolled in the study"
      },
      {
        "id": "pop_3",
        "name": "Full Analysis Set",
        "text": "The Full Analysis Set (FAS) includes all participants who were enrolled and received at least 1 dose of ALXN1840.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "FAS",
        "populationDescription": "The Full Analysis Set (FAS) includes all participants who were enrolled and received at least 1 dose of ALXN1840.",
        "criteria": "Enrolled AND received >=1 dose of ALXN1840"
      },
      {
        "id": "pop_4",
        "name": "Per Protocol Set",
        "text": "The Per Protocol (PP) Set includes all participants in the FAS who did not have any major protocol deviations that would impact the primary efficacy endpoint.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "PP",
        "populationDescription": "The Per Protocol (PP) Set includes all participants in the FAS who did not have any major protocol deviations that would impact the primary efficacy endpoint.",
        "criteria": "In FAS AND no major protocol deviations impacting primary efficacy endpoint"
      },
      {
        "id": "pop_5",
        "name": "Safety Set",
        "text": "The Safety Set includes all participants who received at least 1 dose of ALXN1840.",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "Safety Set",
        "populationDescription": "The Safety Set includes all participants who received at least 1 dose of ALXN1840.",
        "criteria": "Received >=1 dose of ALXN1840"
      },
      {
        "id": "pop_6",
        "name": "Pharmacokinetic Analysis Set",
        "text": "The Pharmacokinetic (PK) Analysis Set includes all participants who received at least 1 dose of ALXN1840 and have at least 1 evaluable PK concentration.",
        "populationType": "PK/PD",
        "instanceType": "AnalysisPopulation",
        "label": "PK Analysis Set",
        "populationDescription": "The Pharmacokinetic (PK) Analysis Set includes all participants who received at least 1 dose of ALXN1840 and have at least 1 evaluable PK concentration.",
        "criteria": "Received >=1 dose of ALXN1840 AND >=1 evaluable PK concentration"
      },
      {
        "id": "pop_7",
        "name": "Pharmacodynamic Analysis Set",
        "text": "The Pharmacodynamic (PD) Analysis Set includes all participants who received at least 1 dose of ALXN1840 and have at least 1 evaluable PD concentration.",
        "populationType": "PK/PD",
        "instanceType": "AnalysisPopulation",
        "label": "PD Analysis Set",
        "populationDescription": "The Pharmacodynamic (PD) Analysis Set includes all participants who received at least 1 dose of ALXN1840 and have at least 1 evaluable PD concentration.",
        "criteria": "Received >=1 dose of ALXN1840 AND >=1 evaluable PD concentration"
      }
    ],
    "characteristics": [
      {
        "id": "char_1",
        "name": "Age",
        "code": "AGE",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Age",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Age at baseline in years"
      },
      {
        "id": "char_2",
        "name": "Wilson Disease History",
        "code": "WILSON_DISEASE_HISTO",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Wilson Disease History",
        "dataType": "String",
        "instanceType": "Characteristic",
        "description": "History and characteristics of Wilson Disease"
      },
      {
        "id": "char_3",
        "name": "Prior medications used to treat WD",
        "code": "PRIOR_MEDICATIONS_US",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Prior medications used to treat WD",
        "dataType": "String",
        "instanceType": "Characteristic",
        "description": "Medications used to treat Wilson Disease prior to the study"
      }
    ],
    "summary": {
      "populationCount": 7,
      "characteristicCount": 3
    }
  }
}